Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Stephanie K. Dougan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-2263-363X; OpenAlex author ID A5001285437; NIH RePORTER profile ID 9406399. Sources: OpenAlex.

Their work

Papers
21 (first author 3, last author 8)
Trials
0
Grants
2
Labs led
1
Collaborators
87
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 3 papers · 2023: 3 papers · 2024: 4 papers · 2025: 1 paper · 2026: 4 papers, 2 grants

Papers 21

  1. Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Last author DOI 10.1016/j.ccell.2026.04.005↗
  2. CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. Last author DOI 10.1016/j.cell.2026.08.045↗
  3. Growth factor supportive care for chemotherapy-induced neutropenia suppresses antitumour immunity in checkpoint blockade-responsive pancreatic cancer. Last author DOI 10.1093/immadv/ltag013↗
  4. Autophagy Inhibition Reprograms the Tumor Microenvironment of Pancreatic Cancer to Promote Macrophage Phagocytosis of Tumor Cells. Co-author DOI 10.1158/0008-5472.can-25-2451↗
  5. De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer. Co-author DOI 10.1038/s41467-025-61242-x↗
  6. PD-1 Blockade Induces Reactivation of Nonproductive T-Cell Responses Characterized by NF-κB Signaling in Patients with Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-23-1444↗
  7. Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-1164↗
  8. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-24-0177↗
  9. Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the T… Last author DOI 10.1158/2326-6066.cir-23-1073↗
  10. Ornithine aminotransferase supports polyamine synthesis in pancreatic cancer. Co-author DOI 10.1038/s41586-023-05891-2↗
  11. Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy. Last author DOI 10.1053/j.gastro.2023.05.038↗
  12. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline r… Co-author DOI 10.1136/jitc-2023-007586↗
  13. Translational advances in pancreatic ductal adenocarcinoma therapy. First author DOI 10.1038/s43018-022-00349-2↗
  14. Bicarbonate transport as a vulnerability in pancreatic cancer. First author DOI 10.1038/s43018-022-00492-w↗
  15. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1125↗
  16. Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer. Last author DOI 10.1098/rsob.210245↗
  17. Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-1367↗
  18. Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. Last author DOI 10.1053/j.gastro.2018.12.038↗
  19. Unmasking Pancreatic Cancer: Epitope Spreading After Single Antigen Chimeric Antigen Receptor T-Cell Therapy in a Human Phase I Trial. First author DOI 10.1053/j.gastro.2018.06.023↗
  20. Radiation and Local Anti-CD40 Generate an Effective in situ Vaccine in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.3389/fimmu.2018.02030↗
  21. The Pancreatic Cancer Microenvironment. Co-author DOI 10.1097/ppo.0000000000000288↗

Grants 2

  1. IL21R signaling in CD4 T cells converts transient KRASi responses to long term remissions R01CA303051↗
  2. Stromal modulation of pancreatic cancer malignant cell state and therapeutic sensitivity U01CA274276↗

Closest collaborators

The 25 strongest of 87 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrew J. Aguirre · 8 shared papers, 1 shared grant, 2021–2026 · strength 2.50
  2. Brian Matthew Wolpin · 8 shared papers, 2021–2026 · strength 1.20
  3. Jonathan Andrew Nowak · 8 shared papers, 2021–2026 · strength 1.20
  4. Michael Lawrence Dougan · 5 shared papers, 2023–2026 · strength 1.01
  5. William C. Hahn · 1 shared grant, 2026 · strength 1.00
  6. Harshabad Singh · 6 shared papers, 2021–2026 · strength 0.90
  7. James M. Cleary · 6 shared papers, 2021–2026 · strength 0.90
  8. Joseph Douglas Mancias · 5 shared papers, 2022–2026 · strength 0.85
  9. Megan T. Hoffman · 4 shared papers, 2023–2026 · strength 0.83
  10. Brandon M. Huffman · 5 shared papers, 2021–2026 · strength 0.79
  11. Victoire Cardot‐Ruffino · 5 shared papers, 2023–2026 · strength 0.77
  12. Kimberly J. Perez · 5 shared papers, 2022–2026 · strength 0.77
  13. Andressa Dias Costa · 5 shared papers, 2022–2024 · strength 0.70
  14. Thomas E. Clancy · 4 shared papers, 2022–2026 · strength 0.65
  15. Lestat R. Ali · 4 shared papers, 2023–2026 · strength 0.63
  16. Douglas Adam Rubinson · 4 shared papers, 2022–2026 · strength 0.62
  17. Brendan D. Parent · 2 shared papers, 2026 · strength 0.54
  18. Qiang Li · 2 shared papers, 2022–2026 · strength 0.52
  19. Osama E. Rahma · 3 shared papers, 2023–2024 · strength 0.44
  20. Srivatsan Raghavan · 3 shared papers, 2021–2024 · strength 0.42
  21. Courtney T.S. Kureshi · 2 shared papers, 2026 · strength 0.38
  22. Chong Zuo · 2 shared papers, 2026 · strength 0.38
  23. George Molina · 2 shared papers, 2026 · strength 0.38
  24. Craig Lee Slingluff · 2 shared papers, 2023–2024 · strength 0.30
  25. Matthew H. G. Katz · 2 shared papers, 2023–2024 · strength 0.30

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.